A5044848112- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Parathyroid Disorders and Treatments
- Cardiac Valve Diseases and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiac Imaging and Diagnostics
- Hemodynamic Monitoring and Therapy
- Heart rate and cardiovascular health
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cardiac Structural Anomalies and Repair
- Medication Adherence and Compliance
- Eosinophilic Disorders and Syndromes
- Health Systems, Economic Evaluations, Quality of Life
- Acute Myocardial Infarction Research
- Sarcoidosis and Beryllium Toxicity Research
- Cardiomyopathy and Myosin Studies
- Potassium and Related Disorders
- Blood Pressure and Hypertension Studies
- GDF15 and Related Biomarkers
- Cardiac, Anesthesia and Surgical Outcomes
- Magnesium in Health and Disease
- Heart Rate Variability and Autonomic Control
- Ultrasound in Clinical Applications
- Frailty in Older Adults
Zuyderland Medisch Centrum
2021-2024
Maastricht University Medical Centre
2012-2022
Northwestern University
2019-2020
Maastricht University
2012-2020
University Medical Center
2013-2020
KU Leuven
2014
Kantonsspital St. Gallen
2013
University Hospital of Bern
2013
Psychiatry Baselland
2013
Luzerner Kantonsspital
2013
A systemic proinflammatory state has been hypothesized to mediate the association between comorbidities and abnormal cardiac structure/function in heart failure with preserved ejection fraction (HFpEF). We conducted a proteomic analysis investigate this paradigm.In 228 patients HFpEF from multicenter PROMIS-HFpEF study (Prevalence of Microvascular Dysfunction Heart Failure With Preserved Ejection Fraction), 248 unique circulating proteins were quantified by multiplex immunoassay (Olink) used...
Abstract Awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) has increased over the years due to diagnostic and therapeutic developments. Timely initiation novel disease-modifying treatments improves both morbidity mortality, which underlines necessity for a prompt diagnosis. Nevertheless, early diagnosis ATTR-CM remains challenging. This is retrospective observational cohort study patients diagnosed with ATTR-CM. Between 2016 2023, 87 were cardiac amyloidosis 65 (75%) 22 (25%) light...
Rationale: To maintain cardiac mechanical and structural integrity after an ischemic insult, profound alterations occur within the extracellular matrix. Osteoglycin is a small leucine-rich proteoglycan previously described as marker of hypertrophy. Objective: establish whether osteoglycin may play role in function myocardial infarction (MI). Methods Results: expression associated with collagen deposition scar formation mouse human MI. Absence mice resulted significantly increased...
Background: Improvement of left ventricular function (also called reverse remodeling [LVRR]) is an important treatment goal in patients with dilated cardiomyopathy (DCM) and hypokinetic non-DCM (HNDC) prognostically favorable. We tested whether genetic DCM mutations impact LVRR independent from clinical parameters. Methods Results: Patients (n=346; mean ejection fraction, 30%) underwent genotyping for 47 DCM-associated genes addition to extensive phenotyping. was defined as improvement...
Abstract Cardiac amyloidosis (CA)—mostly transthyretin-related (ATTR-CA)—has recently gained interest in cardiology. Bone scintigraphy (BS) is one of the main screening tools for ATTR-CA but also used various other reasons. The objective was to evaluate whether all CA cases are detected and what happens during follow-up. All routine BS performed at Maastricht University Medical Center (May 2012–August 2020) were screened presence CA. Scans suspected excluded. A Perugini stage ≥1 classified...
Heart failure (HF) and frailty frequently coexist may share a common pathobiology, although the underlying mechanisms remain unclear. Understanding these provide guidance for preventing treating both conditions.
Therapy guided by N-terminal-pro-B-type natriuretic peptide (NT-proBNP) levels may improve outcomes in patients with chronic heart failure (HF), especially younger reduced left ventricular ejection fraction. It remains unclear whether treatment effects persist after discontinuation of the NT-proBNP-guided strategy.Trial Intensified versus standard Medical therapy Elderly Congestive Heart Failure randomized 499 HF aged≥60 years fraction≤45% to intensified, standard, symptom-guided into...
Background: β-Blockers (BBs) are mainstay therapy for heart failure with reduced ejection fraction. However, individual patient responses to BB vary, which may be partially due genetic variation. The goal of this study was derive and validate the first polygenic response predictor (PRP) survival benefit in fraction patients. Methods: Derivation validation analyses were performed n=1436 total HF patients European descent <50%. PRP derived a random subset Henry Ford Heart Failure...
Abstract Aims We sought to compare the generalizability and prognostic implications of heart failure with preserved ejection fraction (HFpEF) scores (HFA‐PEFF H 2 FPEF score) in Treatment Preserved Cardiac Function Heart Failure an Aldosterone Antagonist (TOPCAT) Phosphodiesterase‐5 Inhibition Improve Clinical Status Exercise Capacity Ejection Fraction (RELAX) trial participants matched controls from Atherosclerosis Risk Community (ARIC) study. Methods results Based on respective scores,...
Abstract Aims This study assessed the prognostic implications of mechanical atrial dysfunction in heart failure with preserved ejection fraction (HFpEF) patients different stages fibrillation (AF) detail. Methods and results HFpEF (n = 258) systemically underwent an extensive clinical characterization, including 24-h Holter monitoring speckle-tracking echocardiography. Patients were categorized according to rhythm AF: 112 no history AF (no AF), 56 paroxysmal (PAF), 90 sustained...
Abstract Aims Whether and how iron deficiency (ID) impacts patients with heart failure (HF) preserved ejection fraction (HFpEF) remain unclear. The aim of our study was to investigate the impact ID on functional status, exercise capacity, prognosis in HFpEF. Methods results population consisted 300 HFpEF patients. defined as serum ferritin <100 μg/L or 100–300 transferrin‐saturation <20%. Baseline quality life (HADS score EQ 5D index), 6 min walking test, echocardiography, outcome...
It is common practice for clinicians to advise fluid restriction in patients with heart failure (HF), but data from clinical trials are lacking. Moreover, associated thirst distress and may adversely impact quality of life (QoL). To address this gap evidence, the Fluid REStriction Heart vs liberal UPtake (FRESH-UP) study was initiated.The FRESH-UP a randomized, controlled, open-label, multicenter trial investigate effects 3-month period intake (1500 mL/day) on QoL outpatients chronic HF (New...
Abstract Aims Heart failure (HF) represents a clinical syndrome resulting from different aetiologies and degrees of heart diseases. Among these, key role is played by primary muscle disease (cardiomyopathies), which are the combination multifactorial environmental insults in presence or absence known genetic predisposition. The aim Maastricht Cardiomyopathy registry (mCMP‐registry; NCT04976348) to improve (early) diagnosis, risk stratification, management cardiomyopathy phenotypes beyond...
Abstract Aim Fibroblast growth factor 23 (FGF23) is an intensively studied biomarker at the crossroads of cardiovascular disease, heart failure (HF) and chronic kidney disease. Independent associations between increasing FGF23 levels events were found in many, but not all studies. By analysing data from TIME‐CHF cohort, we sought to investigate prognostic value elderly, multimorbid HF patient cohort. We determined differences intact (iFGF23) C‐terminal (cFGF23) regarding their over time...